FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-05
Target enrollment:
Participant gender:
Summary
Based on promising data from our laboratory demonstrating synergy between ablative local
radiotherapy and FLT3 ligand immunotherapy in murine NSCLC models, investigators are
performing a phase II study combining FLT3L immunotherapy and SBRT for patients with advanced
NSCLC that has progressed following standard systemic therapy. All patients will receive
daily subcutaneous injections of CDX-301 (75 µg/kg) for 5 days, beginning on the first day of
SBRT. SBRT will be delivered to a single pulmonary or extrapulmonary lesion. The SBRT regimen
will depend on the size and location of the target lesion. The primary endpoint will be
progression-free survival at 4 months, defined using immune-related response criteria (irRC).
A total of 29 patients will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University